Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M

Core Points - Biohaven Ltd. has successfully closed its underwritten public offering of 26,833,334 common shares, raising approximately $200 million in gross proceeds, which includes the full exercise of the underwriters' option to purchase an additional 3,500,000 shares at a public offering price of $7.50 per share [1][7] - The offering was upsized from an initially announced size of $150 million to $175 million, indicating strong demand for the shares [1] - The net proceeds from the offering will be used for general corporate purposes, although specific allocations have not been detailed [1] Company and Industry Summary - Biohaven Ltd. is a global clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for a wide range of rare and common diseases [1][8] - The offering was managed by a consortium of financial institutions, including J.P. Morgan, Goldman Sachs & Co. LLC, Leerink Partners, TD Cowen, and Cantor Fitzgerald [2] - The shares were issued under an effective shelf registration statement on Form S-3, allowing for streamlined access to capital markets [4]